Danaher Corporation's Stock Analysis

Danaher Shareholders Approve Incentive Plan and Director Elections

On May 5, 2026, Danaher Corporation held its annual meeting where shareholders approved several key proposals. Among these was the Amended and Restated Danaher Corporation Omnibus Incentive Plan, which increases the share reserve by 20 million shares and extends the plan term to May 5, 2036. Shareholders also elected eleven directors to terms expiring in 2027 and ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.

Additionally, shareholders approved the advisory vote on the compensation of the Company's named executive officers. Each proposal received favorable votes from the shareholders, indicating support for the Company's governance and compensation practices. This meeting and the resulting approvals may have implications for the Company's operational strategies and stock performance moving forward.

May 07, 2026 16:36:15

Danaher Issues €3 Billion in Senior Notes for Acquisition

Danaher Corporation has issued €500 million in Floating Rate Senior Notes due 2028, €750 million in 3.250% Senior Notes due 2030, €750 million in 3.625% Senior Notes due 2034, and €1 billion in 4.000% Senior Notes due 2038, totaling €3 billion. The proceeds from this offering will primarily be used to fund the cash consideration for the proposed acquisition of Masimo Corporation, along with covering associated costs. The Notes rank equally with Danaher’s other unsecured senior debt and include provisions for redemption under specific conditions.

The Notes will pay interest quarterly or annually, depending on the series, and Danaher has the option to redeem them early under certain circumstances. If the acquisition of Masimo does not occur by a specified date, Danaher is obligated to redeem the Fixed Rate Notes at a premium. The indenture governing the Notes includes covenants that restrict Danaher’s ability to incur secured debt or engage in significant asset transfers, and it outlines conditions that could lead to the acceleration of payment obligations in the event of default.

Apr 29, 2026 16:14:44

Danaher Reports First Quarter 2026 Financial Results

Danaher Corporation reported net earnings of $1.0 billion, or $1.45 per diluted share, for the first quarter of 2026, reflecting a 9.5% increase in non-GAAP adjusted diluted net earnings per share to $2.06. Revenues rose by 3.5% year-over-year to $6.0 billion, with non-GAAP core revenue increasing by 0.5%. The company generated $1.3 billion in operating cash flow and $1.1 billion in non-GAAP free cash flow, contributing to an increase in full-year earnings guidance to a range of $8.35 to $8.55 per share.

The company highlighted strong performance in its Bioprocessing and Life Sciences segments, which offset a lighter-than-expected respiratory season. Danaher also announced plans to acquire Masimo Corporation, aiming to enhance operational performance through its existing business systems. For the second quarter, the company expects non-GAAP core revenue to grow in the low-single digits year-over-year, while maintaining a full-year revenue growth forecast of 3% to 6%.

Apr 20, 2026 17:44:45

Danaher Secures $5 Billion Credit Facility for Liquidity Support

Danaher Corporation has established a new $5.0 billion 364-day revolving credit facility, which will expire on April 15, 2027. This facility, arranged with Bank of America and other lenders, allows Danaher to convert outstanding loans into term loans under certain conditions. The interest rates on borrowings will vary based on Danaher’s long-term debt credit rating, and the company is required to maintain a Consolidated Leverage Ratio of 0.65 to 1.00 or less. Danaher’s obligations under this facility are unsecured, and the company has guaranteed the obligations of its subsidiaries that may borrow under this facility.

The credit facility will be utilized for liquidity support for Danaher’s U.S. dollar-denominated commercial paper program and for general corporate purposes. It includes standard covenants that restrict certain actions by Danaher and its subsidiaries, such as incurring liens or selling significant assets. Events of default, including changes of control, could lead to the immediate repayment of outstanding obligations under the agreement. Danaher is also subject to a per annum facility fee based on the total commitments under the credit facility.

Apr 17, 2026 08:28:34

Danaher to Acquire Masimo for $180 Per Share

Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion including debt. The merger will see Masimo continue as a wholly owned subsidiary of Danaher and is expected to close in the second half of 2026, pending regulatory approvals and shareholder consent. Danaher anticipates that the acquisition will enhance its diagnostics segment and is expected to yield significant annual cost and revenue synergies over the next five years.

Upon completion, Masimo is projected to contribute positively to Danaher’s earnings, with an estimated adjusted diluted net earnings increase of $0.15 to $0.20 in the first full year and around $0.70 by the fifth year post-acquisition. Danaher expects Masimo to achieve more than $530 million in EBITDA by 2027, alongside anticipated annual synergies of over $175 million. The acquisition is expected to strengthen Danaher's position in the diagnostics market, particularly in acute care settings.

Feb 17, 2026 08:08:12

Danaher Board Member Jessica Mega Announces Retirement

Jessica L. Mega has informed Danaher Corporation's Board of Directors that she will retire from her position effective February 5, 2026. Her decision to step down is attributed to commitments related to her other professional obligations and is not due to any disagreements with the company regarding its operations or policies.

This change in the Board's composition may be of interest to investors as it reflects potential shifts in governance and oversight at Danaher. The company has confirmed that Dr. Mega's retirement is amicable, ensuring continuity in its leadership and strategic direction.

Feb 10, 2026 16:22:59

Danaher Reports Financial Results for 2025 Fiscal Year

Danaher Corporation reported its financial results for the fourth quarter and full year of 2025, highlighting net earnings of $1.2 billion for Q4, or $1.66 per diluted share, and $3.6 billion for the full year, equating to $5.03 per diluted share. Revenue for Q4 increased by 4.5% to $6.8 billion, while full-year revenue rose by 3.0% to $24.6 billion. The company generated $2.1 billion in operating cash flow in Q4 and $6.4 billion for the full year, with non-GAAP free cash flow reported at $1.8 billion and $5.3 billion, respectively.

In 2025, Danaher launched several innovative products aimed at enhancing its position in life sciences and diagnostics, including advancements in bioprocessing and diagnostics technologies. For 2026, the company anticipates a low-single digit increase in non-GAAP core revenue for Q1 and a projected growth of 3% to 6% for the full year. Additionally, Danaher has initiated guidance for adjusted diluted net earnings per share in the range of $8.35 to $8.50.

Jan 27, 2026 17:37:52

Danaher Projects Revenue Growth and Strong Earnings for 2025

Danaher Corporation announced estimated financial performance for the fourth quarter of 2025, projecting mid-single digit revenue growth year-over-year and non-GAAP core revenue growth towards the high end of previously announced guidance. The anticipated adjusted diluted net earnings per share for the full year 2025 is expected to be between $7.70 and $7.80, reflecting a solid finish to the year, particularly in the Bioprocessing, Life Sciences, and Diagnostics segments.

The company emphasized its strong positioning in key markets, with expected core revenue growth of 3% to 6% for 2026. Danaher highlighted its differentiated portfolio and the strength of its business model, which includes a significant portion of recurring revenue. The upcoming quarterly earnings call is scheduled for January 28, 2026, where further details on financial performance and strategic initiatives will be discussed.

Jan 12, 2026 09:07:26

Danaher Board Member John T. Schwieters to Retire in 2026

John T. Schwieters has informed Danaher’s Board of Directors that he will not seek reelection at the 2026 annual meeting and will retire from the Board at that time. His decision is not due to any disagreements regarding the Company’s operations or policies.

Following Mr. Schwieters’ retirement, the size of Danaher’s Board will decrease from thirteen members to twelve. This change will take effect at the 2026 Annual Meeting.

Nov 06, 2025 16:41:45

Danaher Reports Third Quarter 2025 Financial Results and Guidance

Danaher Corporation announced its financial results for the third quarter ending September 26, 2025, reporting net earnings of $908 million, or $1.27 per diluted share, with non-GAAP adjusted earnings at $1.89 per share. Revenues increased by 4.5% year-over-year to $6.1 billion, while non-GAAP core revenue rose by 3.0%. The company generated $1.7 billion in operating cash flow and $1.4 billion in non-GAAP free cash flow, reflecting strong performance driven by its bioprocessing business and respiratory revenue at Cepheid.

For the full year 2025, Danaher is maintaining its adjusted diluted net earnings guidance in the range of $7.70 to $7.80 per share, with an expectation of low-single-digit growth in non-GAAP core revenue. The company has not provided reconciliations for certain non-GAAP measures due to the unpredictability of additional elements that could affect results. Investors can access further details through the company's investor conference call and related webcasts.

Oct 20, 2025 17:39:47